Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047, USA.
Bioorg Med Chem Lett. 2011 Jan 1;21(1):172-5. doi: 10.1016/j.bmcl.2010.11.043. Epub 2010 Nov 11.
The objective of this Letter is both to report the permeability results of a linezolid-based sulfenamide prodrug in an MDCK cell model (enterocyte surrogate system) and to discuss the strategic implications of these results for considering sulfenamide prodrugs to enhance the oral delivery of weakly acidic NH-acids (e.g., amides, ureas, etc.). The two main findings from this study are that the sulfenamide prodrug does not appear to survive intracellular transport due to conversion to linezolid and that there appears to be an apically-oriented surface conversion pathway that can additionally serve to convert the sulfenamide prodrug to linezolid upon approach of the apical membrane. It is hoped that these findings, along with the discussion of the strategic implications, will facilitate a greater awareness of the potential strengths and weaknesses inherent in the sulfenamide prodrug approach for enhancing the oral delivery of weakly acidic NH-acid drugs.
这封信件的目的既是报告一个基于利奈唑胺的亚砜酰胺前药在 MDCK 细胞模型(肠细胞替代系统)中的渗透结果,也是讨论这些结果对于考虑亚砜酰胺前药来增强弱酸性 NH 酸(例如酰胺、脲等)的口服递送的战略意义。这项研究的两个主要发现是,亚砜酰胺前药似乎由于转化为利奈唑胺而不能在细胞内转运,并且似乎存在一个朝向顶端的表面转化途径,当接近顶端膜时,该途径还可以将亚砜酰胺前药转化为利奈唑胺。希望这些发现以及对战略意义的讨论将有助于提高对亚砜酰胺前药方法增强弱酸性 NH 酸药物口服递送的固有优势和劣势的认识。